The Complexity of Prescribing Intravenous Lipid Emulsions

Imagem de Miniatura
Arquivos
art_WAITZBERG_The_Complexity_of_Prescribing_Intravenous_Lipid_Emulsions_2015.PDF (920.1 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2015
Editora
KARGER
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
INTRAVENOUS LIPID EMULSIONS, v.112, p.150-162, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Intravenous lipid emulsions (LEs) are relevant for patients receiving parenteral nutrition because they prevent the depletion of essential fatty acids (FAs) and, as a highly dense energy source, enable the reduction of glucose provision, thereby decreasing the risks of hyperglycemia and hepatic impairment. The prescription of LEs is complex, due mainly to their distinct FA components, which may alter the immune response in different ways and distinctly influence inflammation, oxidative stress and blood coagulation according to their biochemical properties. In addition, an excess of other LE components, such as phospholipids and phytosterols, may be associated with hepatic steatosis and dysfunction. These associations do not represent direct risks or obstacles to LE use in metabolically stable patients but can render the choice of the best LE for hypermetabolic patients difficult. The infusion of LEs according to the available guidelines provides more benefit than harm and should be part of exclusive parenteral nutrition regimens or complement enteral nutrition when appropriate. The patient's metabolic profile should guide the type of FA and amount of lipids that are provided. For critically ill hypermetabolic patients, growing evidence indicates that standard LEs based solely on soybean oil should be avoided in favor of new LEs containing medium-chain triglycerides, olive oil, or fish oil to decrease the provision of potentially oxidative, inflammatory/immunosuppressive, and prothrombotic n-6 FAs. In addition, as sources of eicosapentaenoic and docosahexaenoic acids, LEs containing fish oil may be important for critically ill patients because they allow better modulation of the immune response and likely reduce the length of intensive care unity stay. However, current evidence precludes the recommendation of a specific LE for clinical use in this patient population. (C) 2015 S. Karger AG, Basel
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/11664
Referências
  1. Adolph M, 2009, GER MED SCI, V7
  2. Antébi H, 2004, JPEN J Parenter Enteral Nutr, V28, P142, DOI 10.1177/0148607104028003142
  3. Barbosa VM, 2010, CRIT CARE, V14, DOI 10.1186/cc8844
  4. Battistella FD, 1997, J TRAUMA, V43, P52, DOI 10.1097/00005373-199707000-00013
  5. Calder PC, 2010, INTENS CARE MED, V36, P735, DOI 10.1007/s00134-009-1744-5
  6. Calder PC, 2013, P NUTR SOC, V72, P263, DOI 10.1017/S0029665113001250
  7. Cano NJM, 2006, BRIT J NUTR, V95, P152, DOI 10.1079/BJN20051595
  8. Chen B, 2010, JPEN-PARENTER ENTER, V34, P387, DOI 10.1177/0148607110362532
  9. CLARKE PJ, 1987, BRIT J SURG, V74, P701, DOI 10.1002/bjs.1800740818
  10. Crimi E, 2006, FREE RADICAL BIO MED, V40, P398, DOI 10.1016/j.freeradbiomed.2005.10.054
  11. Demirer S, 2000, CLIN NUTR, V19, P253, DOI 10.1054/clnu.2000.0101
  12. Dhaliwal R, 2014, NUTR CLIN PRACT, V29, P29, DOI 10.1177/0884533613510948
  13. ELMADFA I, 1993, ANN NUTR METAB, V37, P8, DOI 10.1159/000177743
  14. Furukawa K, 2002, NUTRITION, V18, P235, DOI 10.1016/S0899-9007(01)00784-5
  15. Gelas P, 1998, JPEN-PARENTER ENTER, V22, P67, DOI 10.1177/014860719802200267
  16. Gobel Y, 2003, J PEDIATR GASTR NUTR, V37, P161, DOI 10.1097/00005176-200308000-00015
  17. GOGOS CA, 1994, J AM COLL NUTR, V13, P40
  18. Goulet O, 1999, AM J CLIN NUTR, V70, P338
  19. Grimm H, 2006, EUR J NUTR, V45, P55, DOI 10.1007/s00394-005-0573-8
  20. Han YY, 2012, NUTR CLIN PRACT, V27, P91, DOI 10.1177/0884533611429796
  21. Hardy G, 1997, NUTRITION, V13, P230, DOI 10.1016/S0899-9007(96)00040-8
  22. Jarstrand C, 1978, JPEN J Parenter Enteral Nutr, V2, P663, DOI 10.1177/0148607178002005663
  23. Klek S, 2013, CLIN NUTR, V32, P224, DOI 10.1016/j.clnu.2012.06.011
  24. Kuse ER, 2002, TRANSPLANT INT, V15, P272, DOI 10.1007/s00147-002-0393-1
  25. Laviano A, 2010, S AFR J CLIN NUTR, V23, pS08
  26. LOO LS, 1982, J INFECT DIS, V146, P64
  27. Manuel-y-Keenoy B, 2002, EUR J CLIN NUTR, V56, P121, DOI 10.1038/sj.ejcn.1601294
  28. Manzanares W, 2013, INTENS CARE MED, V39, P1683, DOI 10.1007/s00134-013-2999-4
  29. Manzanares W, 2014, JPEN-PARENTER ENTER, V38, P20, DOI 10.1177/0148607113486006
  30. Mateu-de Antonio Javier, 2008, Br J Nutr, V99, P846
  31. MEGUID MM, 1984, ARCH SURG-CHICAGO, V119, P1294
  32. Meguid M M, 1982, JPEN J Parenter Enteral Nutr, V6, P304, DOI 10.1177/0148607182006004304
  33. NORDENSTROM J, 1979, AM J CLIN NUTR, V32, P2416
  34. Onar P, 2011, NUTR CLIN PRACT, V26, P61, DOI 10.1177/0884533610392920
  35. PALUZZI M, 1987, SURGERY, V102, P711
  36. PORTA I, 1994, INFUSIONSTHERAPIE, V21, P316
  37. Pradelli L, 2012, CRIT CARE, V16, DOI 10.1186/cc11668
  38. Reimund JM, 2005, ALIMENT PHARM THERAP, V21, P445, DOI 10.1111/j.1365-2036.2005.02354.x
  39. Roulet M, 1997, JPEN-PARENTER ENTER, V21, P296, DOI 10.1177/0148607197021005296
  40. Schade I, 2008, CRIT CARE S2, V12, ps56
  41. SEDMAN PC, 1991, BRIT J SURG, V78, P1396, DOI 10.1002/bjs.1800781142
  42. Singer P, 2011, MINERVA ANESTESIOL, V77, P1115
  43. Siqueira J, 2011, J CLIN ENDOCR METAB, V96, P3207, DOI 10.1210/jc.2011-0480
  44. Staun M, 2009, CLIN NUTR, V28, P467, DOI 10.1016/j.clnu.2009.04.001
  45. Thomas-Gibson S, 2004, CLIN NUTR, V23, P697, DOI 10.1016/j.clnu.2003.11.007
  46. Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
  47. Umpierrez GE, 2012, CRIT CARE MED, V40, P1792, DOI 10.1097/CCM.0b013e3182474bf9
  48. vanderPoll T, 1996, THROMB HAEMOSTASIS, V75, P83
  49. Verdier P, 2002, NUTR CLIN METAB, V16, P85, DOI 10.1016/S0985-0562(02)00115-2
  50. Waitzberg DL, 2009, NUTR CLIN PRACT, V24, P487, DOI 10.1177/0884533609339071
  51. Waitzberg DL, 2006, JPEN-PARENTER ENTER, V30, P351, DOI 10.1177/0148607106030004351
  52. Wang J, 2012, NUTRITION, V28, P623, DOI 10.1016/j.nut.2011.08.004
  53. Wichmann MW, 2007, CRIT CARE MED, V35, P700, DOI 10.1097/01.CCM.0000257465.60287.AC

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/35